Literature DB >> 19095153

Melanoma and genetics.

Andrew A Nelson1, Hensin Tsao.   

Abstract

As the incidence of malignant melanoma continues to increase and with the completion of the sequencing of the human genome, there have been increasing efforts to identify the "melanoma gene(s)." Although some patients and families have significantly increased risks due to genetic predisposition, most melanoma cases are sporadic and likely result from low to moderate risk genetic factors. This review focuses on the genes that cover the greatest risk of developing melanoma. It is important to remember that many--if not most--cases of melanoma are the result of undiscovered variants. The strongest genetic risk for the development of melanoma results from heritable alterations in cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, which encodes two separate but related proteins, p16/INK4a and p14/ARF. These proteins help regulate cell division and apoptosis, both of which are necessary to maintain cellular homeostasis. Other important genes include CDK4/6 and retinoblastoma (RB1), which encode downstream proteins in the same pathway as p16/INK4a and p14/ARF. Finally, we discuss the relative importance of the melanocortin 1 receptor (MC1R) gene as a moderate risk factor for melanoma. Although great advances have been made in understanding the molecular basis and genetic predisposition of melanoma, many questions still remain to be answered. Someday soon, it will be possible to predict a patient's risk of melanoma by DNA analysis; however, it is important to reconcile our tremendous technologic capabilities with documented clinical utility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19095153     DOI: 10.1016/j.clindermatol.2008.09.005

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  27 in total

1.  Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Authors:  Keith T Flaherty
Journal:  Clin Exp Metastasis       Date:  2012-06-03       Impact factor: 5.150

2.  Personal attributions for melanoma risk in melanoma-affected patients and family members.

Authors:  Jennifer Hay; Marco DiBonaventura; Raymond Baser; Nancy Press; Jeanne Shoveller; Deborah Bowen
Journal:  J Behav Med       Date:  2010-09-01

3.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

4.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

Review 5.  Genetic epidemiology of malignant melanoma susceptibility.

Authors:  Dimitrios Papakostas; Irene Stefanaki; Alexander Stratigos
Journal:  Melanoma Manag       Date:  2015-05-18

Review 6.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 7.  Model Systems for the Study of Malignant Melanoma.

Authors:  Randal K Gregg
Journal:  Methods Mol Biol       Date:  2021

8.  Family risk discussions after feedback on genetic risk of melanoma.

Authors:  Jennifer L Hay; Mallorie Gordon; Yuelin Li
Journal:  JAMA Dermatol       Date:  2015-03       Impact factor: 10.282

9.  Benefits of oral Polypodium Leucotomos extract in MM high-risk patients.

Authors:  P Aguilera; C Carrera; J A Puig-Butille; C Badenas; M Lecha; S González; J Malvehy; S Puig
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-07-31       Impact factor: 6.166

10.  Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

Authors:  Lisa Mirabello; Bin Zhu; Roelof Koster; Eric Karlins; Michael Dean; Meredith Yeager; Matthew Gianferante; Logan G Spector; Lindsay M Morton; Danielle Karyadi; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Lei Song; Nathan Pankratz; Maisa Pinheiro; Julie M Gastier-Foster; Richard Gorlick; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Ana Patino-Garcia; Fernando Lecanda; Miriam Gutierrez-Jimeno; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; Adrienne M Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Nilgün Kurucu; Inci Ergurhan Ilhan; Mandy L Ballinger; David M Thomas; Donald A Barkauskas; Gerardo Mejia-Baltodano; Patricia Valverde; Belynda D Hicks; Bin Zhu; Mingyi Wang; Amy A Hutchinson; Margaret Tucker; Joshua Sampson; Maria T Landi; Neal D Freedman; Susan Gapstur; Brian Carter; Robert N Hoover; Stephen J Chanock; Sharon A Savage
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.